Calystegine B3 as a specific inhibitor for cytoplasmic α-mannosidase, Man2C1

Atsushi Kato*, Li Wang, Kumiko Ishii, Junichi Seino, Naoki Asano, Tadashi Suzuki

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Cytoplasmic α-mannosidase (Man2C1) has been implicated in non-lysosomal catabolism of free oligosaccharides derived from N-linked glycans accumulated in the cytosol. Suppression of Man2C1 expression reportedly induces apoptosis in various cell lines, but its molecular mechanism remains unclear. Development of a specific inhibitor for Man2C1 is critical to understanding its biological significance. In this study, we identified a plant-derived alkaloid, calystegine B3, as a potent specific inhibitor for Man2C1 activity. Biochemical enzyme assay revealed that calystegine B3 was a highly specific inhibitor for Man2C1 among various α-mannosidases prepared from rat liver. Consistent with this in vitro result, an in vivo experiment also showed that treatment of mammalian-derived cultured cells with this compound resulted in drastic change in both structure and quantity of free oligosaccharides in the cytosol, whereas no apparent change was seen in cell-surface oligosaccharides. Calystegine B3 could thus serve as a potent tool for the development of a highly specific in vivo inhibitor for Man2C1.

Original languageEnglish
Pages (from-to)415-422
Number of pages8
JournalJournal of Biochemistry
Volume149
Issue number4
DOIs
StatePublished - 2011/04/01

Keywords

  • calystegine
  • cytosol
  • free oligosaccharides
  • mannosidase
  • swainsonine

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Calystegine B3 as a specific inhibitor for cytoplasmic α-mannosidase, Man2C1'. Together they form a unique fingerprint.

Cite this